AstraZeneca DEP® candidate advance triggers milestone to Starpharma

Apr 20th, 2017

 Starpharma announced the achievement of a key preclinical milestone for its DEP® drug delivery technology in combination with a proprietary oncology molecule from AstraZeneca.

Read More

Melbourne-based company develops world's first anti-viral condom

Apr 12th, 2017

 

The ABC notes Starpharma as the Melbourne company developed the world’s first anti-viral condom using its VivaGel® active in the condom lubricant. VivaGel® has been shown to inactivate HIV, herpes, human papillomavirus and the Zika virus in laboratory studies.

 Go to the article (external link)

Read More

Ansell launches VivaGel® condom in Canada

Apr 12th, 2017

Starpharma is pleased to announce the VivaGel® condom has been launched in Canada by Ansell under the LifeStyles® Dual Protect brand. 

Read More

VivaGel BV phase 3 trials for prevention of BV completed

Mar 30th, 2017

Biotech Dispatch reports Starpharma’s recently completed its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis, noting that top-line results are expected in 2Q 2017.

 Go to the article (external link)

Read More

VivaGel® BV phase 3 trials for prevention of BV completed

Mar 30th, 2017

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced completion of its international, multicentre, phase 3 clinical studies evaluating VivaGel® BV for the prevention of recurrent bacterial vaginosis (rBV). Starpharma expects topline results of the trials to be available in the second quarter of 2017.

Read More

Interim Report and Half-Yearly Financial Results

Feb 27th, 2017

Starpharma released its interim report and financial results for the half-year ended 31 December 2016.

 

Financial Summary

  • Reported loss of $9.0M (Dec 2015: $10.0M)
  • R&D tax incentives of $1.7M reported in the half-year (Dec 2015: $1.8M)
  • Cash position at 31 December 2016 of $36.3M (June 2016: $46.0M)
  • Receipt of $3.5M R&D tax incentive refund from FY16
Read More

Appendix 4C - Quarterly Cashflow Report

Jan 31st, 2017

Starpharma released its Appendix 4C – Quarterly Cashflow report for the period ended 31 December 2016.

Read More

Shareholder Update January 2017

Jan 19th, 2017

In this issue:

›› Enrolment completed for phase 3 program: VivaGel® BV for prevention of recurrence

›› VivaGel® BV granted QIDP and Fast Track designation by US FDA

›› Favourable revision to FDA guidance for BV Treatment

›› VivaGel® condom approved in Canada; licensed in China and Iran

›› New DEP® partnered programs with AstraZeneca and world leading antibody-drug conjugate companies

›› DEP® docetaxel phase 1 program in final expansion phase; preparations underway for phase 2

›› DEP® cabazitaxel shows no neutropenia

›› DEP® irinotecan internal program shows superior performance

Download: Shareholder January 2017 (pdf file, 751kb)


Read More

Starpharma VivaGel® BV gets FDA fast track

Jan 13th, 2017

The Australian reports that Bell Potter sees further upside for Starpharma, setting its share price target at $1.05, given the company had been granted Qualified Infectious Disease Product (QIDP) and fast track designation for VivaGel® BV by the US Food and Drug Administration.

 Go to the article (external link)

Read More

VivaGel® BV granted QIDP and Fast Track designation by US FDA

Jan 12th, 2017

Starpharma Holdings Ltd (ASX: SPL, OTCQX: SPHRY) today announced it has been granted Qualified Infectious Disease Product (QIDP) and Fast Track designation for VivaGel® BV by the US Food and Drug Administration (FDA).

Read More

Starpharma receives $3.5M R&D tax incentive refund

Dec 22nd, 2016

Starpharma Holdings Ltd today announced it has received the anticipated $3.5M of R&D tax incentive refund related to FY16 expenditures. 

Read More

AGM Chairman’s address and CEO presentation

Nov 29th, 2016

Chairman’s address and the CEO’s presentation to the 2016 Annual General Meeting of Starpharma Holdings Limited (ASX: SPL, OTCQX: SPHRY).

Read More